Salih HR - Search Results

1

Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion.

Paczulla AM, Rothfelder K, Raffel S, Konantz M, Steinbacher J, Wang H, Tandler C, Mbarga M, Schaefer T, Falcone M, Nievergall E, Dörfel D, Hanns P, Passweg JR, Lutz C, Schwaller J, Zeiser R, Blazar BR, Caligiuri MA, Dirnhofer S, Lundberg P, Kanz L, Quintanilla-Martinez L, Steinle A, Trumpp A, Salih HR, Lengerke C. Paczulla AM, et al. Among authors: salih hr. Nature. 2019 Aug;572(7768):254-259. doi: 10.1038/s41586-019-1410-1. Epub 2019 Jul 17. Nature. 2019. PMID: 31316209 Free PMC article.

2

Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding.

Salih HR, Rammensee HG, Steinle A. Salih HR, et al. J Immunol. 2002 Oct 15;169(8):4098-102. doi: 10.4049/jimmunol.169.8.4098. J Immunol. 2002. PMID: 12370336

3

Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia.

Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG, Steinle A. Salih HR, et al. Blood. 2003 Aug 15;102(4):1389-96. doi: 10.1182/blood-2003-01-0019. Epub 2003 Apr 24. Blood. 2003. PMID: 12714493 Free article.

4

Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.

Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, Steinle A, Salih HR. Armeanu S, et al. Among authors: salih hr. Cancer Res. 2005 Jul 15;65(14):6321-9. doi: 10.1158/0008-5472.CAN-04-4252. Cancer Res. 2005. PMID: 16024634

5

Soluble MICA in malignant diseases.

Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih HR. Holdenrieder S, et al. Among authors: salih hr. Int J Cancer. 2006 Feb 1;118(3):684-7. doi: 10.1002/ijc.21382. Int J Cancer. 2006. PMID: 16094621

6

Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA.

Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih HR. Holdenrieder S, et al. Among authors: salih hr. Cancer Immunol Immunother. 2006 Dec;55(12):1584-9. doi: 10.1007/s00262-006-0167-1. Epub 2006 Apr 25. Cancer Immunol Immunother. 2006. PMID: 16636811 Free PMC article.

7

Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients.

Salih HR, Goehlsdorf D, Steinle A. Salih HR, et al. Hum Immunol. 2006 Mar;67(3):188-95. doi: 10.1016/j.humimm.2006.02.008. Epub 2006 Mar 29. Hum Immunol. 2006. PMID: 16698441

8

Soluble NKG2D ligands in hepatic autoimmune diseases and in benign diseases involved in marker metabolism.

Holdenrieder S, Eichhorn P, Beuers U, Samtleben W, Stieber P, Nagel D, Peterfi A, Steinle A, Salih HR. Holdenrieder S, et al. Among authors: salih hr. Anticancer Res. 2007 Jul-Aug;27(4A):2041-5. Anticancer Res. 2007. PMID: 17649819 Free article.

9

Soluble NKG2D ligands: prevalence, release, and functional impact.

Salih HR, Holdenrieder S, Steinle A. Salih HR, et al. Front Biosci. 2008 May 1;13:3448-56. doi: 10.2741/2939. Front Biosci. 2008. PMID: 18508446 Review.

10

Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma.

Armeanu S, Krusch M, Baltz KM, Weiss TS, Smirnow I, Steinle A, Lauer UM, Bitzer M, Salih HR. Armeanu S, et al. Among authors: salih hr. Clin Cancer Res. 2008 Jun 1;14(11):3520-8. doi: 10.1158/1078-0432.CCR-07-4744. Clin Cancer Res. 2008. PMID: 18519785

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

226 results

Search Page

Filters